All HealthRX patients on tirzepatide receive a structured follow-up schedule: a two-week check-in after initiation, monthly visits during dose titration, and quarterly visits once a stable dose is reached
Under additional investigation of trial design, what meets the eye is quite intriguing
Eli Lilly is also conducting a phase-3 trial called SURPASS-CVOT, which explores the potential benefits of tirzepatide for cardiovascular health in T2D patients [9]
These include surgery, infection, dehydration, fasting and reduced carbohydrates intake, and in patients with type 1 diabetes too drastic reduction of insulin dose
Khan NA, Auranen M, Paetau I, Pirinen E, Euro L, Forsstrom S,